Institutional accumulation regime. Strong business quality combined with supportive market trend. Valuations remain demanding and supported by current metrics.
SENTINEL REVIEW
AstraZeneca Pharma India Limited (ASTRAZEN)โขUpdated yesterday
๐จ Structural Deterioration Signature: In FY2026, AstraZeneca Pharma India Limited is experiencing severe operating deterioration, marked by a 62.0% YoY deterioration in reported net profit to โน187.5 Cr and persistent margin compression. Profitability is being hollowed out by intensifying cost-push pressure, with EBIT margins falling to 8.1% from 11.1% YoY, signaling significant internal efficiency stress. This operating deterioration is reflected in a severe cash conversion deficit: operating cash flow of โน-15.1 Cr stands against a net profit of โน187.5 Cr, contributing to a 123.2% YoY contraction in cash generation. Against this liquidity strain, total debt remains nominal at โน0.0 Cr, but interest coverage has weakened to -137.79x, indicating heightened financial stress.
- โRisk score improved (QoQ change: 0 pts)
- โProfitability margins pressure eased (Margin Compression resolved)
- โInventory Stress resolved this quarter (19.8 pts)
- โNew risk trigger: Universal Inventory Divergence (+13 pts)
- โGrowth expectations are demanding
- โMarket structure is declining (Stage 4)
- โInstitutional flow regime is Accumulation (0.94ฯ)
- โShare price is up +0.8% this quarter (from โน6,186 on 30 Sept to โน6,237)
- ๐ดInvestigate Operating Leverage Stress and balance sheet impact
- ๐ขInventory Stress resolved in latest filing; verify sustainability in next filing
- ๐ขMaintain routine quarterly surveillance; no governance escalation required
- 13.0 ptsBalance Sheet Stress
- 10.0 ptsGrowth Sustainability
- 12.0 ptsMacro & Sector Calibration
Divergence Radar
Structural Matrix
Risk vs Price TimelineVisualizing the historical relationship between the structural risk score and stock price movement over time.
| Duration | Perf. | Sector Avg | Divergence |
|---|---|---|---|
| 1 Week | +2.59% | -1.46% | +4.05% |
| 1 Month | -0.68% | -6.69% | +6.01% |
| 6 Months | -24.06% | +6.82% | -30.88% |
| 1 Year | -33.05% | +8.93% | -41.97% |
| 2 Year | -11.37% | +47.64% | -59.01% |
| 3 Year | +33.23% | +125.5% | -92.27% |
Business Analysis Methodology
Business analysis focuses on structural risk inside the company. Flagium monitors earnings quality, balance sheet strength, liquidity, governance, competitive position, and growth sustainability to identify areas where risk may be increasing or decreasing before it becomes obvious in reported results.
Financial profile remains stable for now. Pressure has stabilized in balance sheet stress. This suggests the risk profile is currently stabilizing. No major change in risk trend.
Risk Score Composition
Investment Risk Thesis
Current risk score has risen from 5 โ 35 over 14 quarters.
- Inventory turnover
- Operating profit margins
Risk Drivers (Active Warnings)
Primary Driver & Insights
Asset turnover is slowing down due to inventory accumulation. This indicates potential channel stuffing or weaker demand in core product segments.
Active Risk Objects (9)Free Preview (2 of 9)
ASTRAZEN: Inventory growth outpaced Revenue growth by +28.5 pp (Inventory holding ratio increased +27.6%).
Slight build-up in inventory detected. Monitor for slowing sales momentum.
ASTRAZEN: EBITDA margin compressed by 3.0 bps YoY and Raw material costs consumed an additional 6.6% of revenue YoY.
Margins are in freefall. Operating costs are growing significantly faster than revenue.
Unlock All 9 Forensic Signals (7 Additional Warnings Gated)
Free accounts preview the top 2 highest-impact warning signals. Upgrade to Flagium Pro to inspect all 9 active forensic detectors, multi-quarter duration streaks, and financial stress metrics for AstraZeneca Pharma India Limited.
Statutory Note: Forensic signals are algorithmic quantitative observations derived from publicly filed XBRL disclosures and do not constitute allegations of legal misconduct or investment recommendations.
Unlock Interactive Signal Evidence Dossier
Access complete multi-quarter financial evidence, 5-KPI snapshot strips, diagnostic hypotheses, and 1-page forensic PDF dossiers for AstraZeneca Pharma India Limited.
Structural Risk Attribution
Deterministic quarter-on-quarter causal decomposition grounded in statutory exchange filings.
Structural History ยท Last 12 QuartersHistorical Trajectory (12Q)
Risk profile remained steady this quarter, as emergence of Universal Inventory Divergence (+13 pts) was offset by improvement in Inventory Stress (-19.8 pts).
12-Quarter Structural Regimes & Landmark Inflections12Q Structural Regimes & Inflections
Risk deteriorated materially (+25.0 pts), driven by new Inventory Stress (+19.8 pts) and new Margin Compression (+10.1 pts).
Business Resilience & Benchmark Context
Overall: HEALTHYPEER COMPARISON MATRIX
Ranked surveillance & credit risk comparison against sector peers
Stable
Stable
Stable
Watch
Watch
Watch
* Peer comparison is based on risk signals, not valuation or returns.
Unlock 5-Year Forensic Divergence Cockpit
Access multi-year visual divergence charts (EBITDA vs CFO Cash Gap, Receivables Decoupling Spread, and Debt vs FCF Burn) for AstraZeneca Pharma India Limited.
FINANCIAL STATEMENTS
Working Capital & Forensic Monitor
Operating Cycle Disclosuresยท8 Fiscal Years
Working Capital Schedule (INR Cr)
| Metric / Ratio | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
Trade Receivables(โน Cr) | 214 | 185 | 153 | 108 | โ | โ | โ | โ |
Inventories(โน Cr) | 1,027 | 548 | 228 | 190 | โ | โ | โ | โ |
Trade Payables(โน Cr) | 783 | 456 | 198 | 228 | โ | โ | โ | โ |
Net Working Capital(โน Cr) | 458 | 277 | 183 | 70 | โ | โ | โ | โ |
Working Capital / Sales(%) | 19.9% | 15.8% | 13.7% | 6.8% | โ | โ | โ | โ |
Cash Conversion & Operating Cycle (Days)
| Metric / Ratio | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
Cash Conversion Cycle (CCC)(days) | 73d | 57d | 51d | 24d | โ | โ | โ | โ |
Debtor Days (DSO)(days) | 34d | 38d | 42d | 38d | โ | โ | โ | โ |
Inventory Days (DIO)(days) | 163d | 114d | 63d | 67d | โ | โ | โ | โ |
Creditor Days (DPO)(days) | 124d | 95d | 54d | 81d | โ | โ | โ | โ |
Forensic Accounting Monitor & Divergences
| Metric / Ratio | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
Receivable Growth vs Sales (ฮ)(%) | -15.6% | -11.3% | +13.1% | โ | โ | โ | โ | โ |
Inventory Growth vs Sales (ฮ)(%) | +56.2% | +108.6% | -9.5% | โ | โ | โ | โ | โ |
Asset Growth vs Sales (ฮ)(%) | -0.1% | +8.8% | -19.8% | โ | โ | โ | โ | โ |
Earnings-to-Cash Divergence (PAT - CFO)(โน Cr) | 203 | 50 | 69 | 41 | -39 | โ | โ | โ |
Accrual Ratio (Accruals / Avg Assets)(%) | 11.6% | 3.9% | 6.7% | 4.2% | โ | โ | โ | โ |
Operating Cash Realisation (CFO / EBITDA)(%) | -5.9% | 25.8% | 45.6% | 33.4% | 121.4% | โ | โ | โ |
Capitalisation Intensity (CWIP / Assets)(%) | โ | โ | โ | โ | โ | โ | โ | โ |
Industry Intelligence
Pharmaceutical Sector KPIs| Operating Driver | Quarter | Current Value | Change (QoQ) | Change (YoY) | Industry Median |
|---|---|---|---|---|---|
Gross Margin โ | Q1 FY2027 | 79.4% | -660 bps โ Profitability contraction | -1880 bps โ Profitability contraction | 64.0% |
Understanding Pharmaceutical KPIs
Concall & Management Takeaways
No investor earnings call transcripts transcribed for this scrip.
Earnings call intelligence is automatically populated when companies conduct quarterly earnings calls with institutional investors and publish transcripts.
Business quality remains stable.
Current forensic pressure is elevated and improving.
Key risks remain concentrated in growth sustainability and operating leverage.
The risk profile is Early Signals and currently consolidating. Recent structural triggers in balance sheet stress suggest a building pressure on the underlying framework. Material forensic traces are visible in core structural metrics, indicating a progressive erosion of structural stability. Continued monitoring is necessary as risk levels remain above institutional safety parameters.
Market Expectation Engine
Investor Translation โข What the market price is expecting
Expectation EngineAt the current price of โน6,237, the market expects this company to grow its revenue by 31.0% every year for the next 5 years. If you think the company will grow faster than 31.0%, current market prices reflect a discount relative to that growth assumption.
Sentinel Takeaway:The market expects future growth significantly above the company's historical delivery. Current market expectations appear demanding relative to the business's track record, resulting in higher expectation risk.
Using the Implied Revenue Model, the market is pricing ASTRAZEN for 31.0% implied revenue growth versus 20.0% observed 3Y revenue CAGR. Current expectations appear demanding, and trailing fundamentals provide moderate support.
Business Delivery Capacity
Performance quality vs historical benchmarksHistorical business performance currently provides limited support for the market's implied growth assumptions. Improvement in revenue growth and operating efficiency would strengthen expectation support.
WHY IS EXPECTATION RISK ELEVATED?
Valuation Context
WHAT MUST HAPPEN FOR CURRENT PRICE TO BE CORRECT?
| Assumption Metric | Required (To justify current price) | Historical Delivery (Average) | Fulfillment Assessment |
|---|---|---|---|
| Revenue Growth (CAGR) | 31.0% | 20.0% | Demanding |
| Operating Margin (EBIT) | 9.5% | 13.6% | Achievable |
| Free Cash Flow Conversion | -8.0% | 19.4% | Achievable |
*Required metrics indicate the operating efficiency and revenue expansion parameters that must be sustained long-term to justify the current stock price.
The current valuation assumes business performance well above the company's historical record. Historical operating performance currently provides limited evidence that these expectations are sustainable. Continued stronger profitability and stronger cash generation would be required to justify current pricing.
Market Structure Methodology
Flagium separates Business Risk from Market Structure. Business analysis explains what is happening inside the company. Market Structure measures how investors are behaving through price trends, momentum, participation, and institutional activity. Divergences between the two often reveal important transitions before they become obvious.
The stock remains in a confirmed Stage 4 declining phase. Although institutional participation has improved, trend quality remains weak and momentum continues to deteriorate. Current price action does not yet confirm a structural recovery.
What Is Driving Market Structure?
Market structure shows partial alignment with the underlying fundamental risk profile.
Market Cycle Stage Analysis
Stan Weinstein 4-Stage CycleMomentum & Institutional Flow
Methodology & Regulatory Disclaimer
Flagium AI is an automated financial data analytics and research platform providing quantitative risk, forensic, and valuation analytics for informational and educational purposes only. Flagium AI is not registered with SEBI as a Research Analyst or Investment Adviser under SEBI regulations. These analytics do not constitute financial planning, investment advice, or recommendations to buy, sell, or hold any security.
Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered Investment Adviser before acting on any data presented.
๐ฌ Flagium Risk Brief โ Track forensic risks on ASTRAZEN & 3 market anomalies weekly
See a sample issue โ